CTSH vs IBM
Cognizant and IBM, both Technology
IBM is the larger company at $234B against $21B. On trailing earnings CTSH is the cheaper of the two at a P/E of 12.9 against 20.1, a gap that is only a bargain if the two are growing at similar rates. Over the past year IBM returned -13% against -14% for CTSH. The RyuScore puts CTSH ahead, 82 against 58 out of 100.
| Figure | CTSH | IBM |
|---|---|---|
| Last close | $59.19 | $227 |
| Market cap | $21B | $234B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 12.9 | 20.1 |
| Dividend yield | 2.1% | 3.0% |
| 1-year return | -14% | -13% |
| 5-year return | -16% | +106% |
| RyuScoresector-relative, 1–10 | 82/100 | 58/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cognizant
Revenue of $5.4B in Q1 2026, net income $662M. Its largest reported line is Health Sciences, 32% of the disclosed total.
IBM
Revenue of $17B in Q2 2026, net income $2.2B. Its largest reported line is Strategy And Technology, 17% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.